<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2183-5985</journal-id>
<journal-title><![CDATA[Acta Portuguesa de Nutrição]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Port Nutr]]></abbrev-journal-title>
<issn>2183-5985</issn>
<publisher>
<publisher-name><![CDATA[Associação Portuguesa de Nutrição]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2183-59852022000100060</article-id>
<article-id pub-id-type="doi">10.21011/apn.2022.2811</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[GLUCOSAMINA :EVIDÊNCIA NO TRATAMENTO DA OSTEOARTRITE]]></article-title>
<article-title xml:lang="en"><![CDATA[GLUCOSAMINE: EVIDENCE IN THE TREATMENT OF OSTEOARTHRITIS]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Queirós]]></surname>
<given-names><![CDATA[Ana Sofia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sousa]]></surname>
<given-names><![CDATA[Leonor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lopes]]></surname>
<given-names><![CDATA[Soraia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Melo]]></surname>
<given-names><![CDATA[Tiago]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baltazar]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Escola Superior de Tecnologia da Saúde de Coimbra do Instituto Politécnico de Coimbra  ]]></institution>
<addr-line><![CDATA[Coimbra ]]></addr-line>
<country>Portugal</country>
</aff>
<pub-date pub-type="pub">
<day>30</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>30</day>
<month>03</month>
<year>2022</year>
</pub-date>
<numero>28</numero>
<fpage>60</fpage>
<lpage>63</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_arttext&amp;pid=S2183-59852022000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_abstract&amp;pid=S2183-59852022000100060&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.pt/scielo.php?script=sci_pdf&amp;pid=S2183-59852022000100060&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[RESUMO A osteoartrite é uma doença crónica degenerativa multifatorial da cartilagem articular, caracterizada por dor nas articulações e perda de função. A glucosamina consiste num amino-monossacarídeo e um componente essencial da cartilagem articular. É produzida endogenamente, mas também pode ser administrada como um fármaco de ação lenta na osteoartrite para a redução dos sintomas. A presente revisão de literatura pretende compreender os efeitos da glucosamina na osteoartrite, mais especificamente, o seu metabolismo, mecanismo de ação, eficácia e segurança. Foi realizada uma pesquisa bibliográfica, com base em artigos publicados nos últimos dez anos, nas bases de dados &#8220;Pubmed&#8221; e &#8220;Sciencedirect&#8221;, utilizando os descritores &#8220;glucosamine&#8221; em associação com &#8220;osteoarthritis&#8221; e &#8220;pharmacokinetics&#8221;. Recorreu-se ainda a recomendações oficiais de organizações de saúde. A glucosamina administrada oralmente é absorvida no duodeno, e transportada pelos GLUT-2 para o interior das células. Este composto participa na via das hexosaminas, contribuindo para a biossíntese de proteoglicanos e glicoproteínas, componentes principais da matriz extracelular da cartilagem. Na osteoartrite, a glucosamina possui efeito anti-inflamatório e protetor da degradação da cartilagem. De acordo com a literatura, a dose terapêutica de glucosamina capaz de diminuir a dor articular e melhorar a função é de 1500 mg/ dia, sendo que a marca e a formulação são fatores essenciais para a sua eficácia. Esta substância foi considerada segura e não foram observados efeitos adversos graves nem casos de sobredosagem. A glucosamina pode ter um efeito positivo no alívio dos sintomas da osteoartrite. No entanto, ainda não há consenso quanto à sua eficácia, interações nutriente-medicamento e efeitos no metabolismo da glucose, sendo necessários mais estudos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Osteoarthritis is a chronic multifactorial degenerative disease of the articular cartilage, characterized by joint pain and loss of function. Glucosamine consists of an amino-monosaccharide and an essential component of articular cartilage. It is produced endogenously, but it can also be administered as a slow-acting drug in osteoarthritis to reduce symptoms. This literature review aims to understand the effects of glucosamine on osteoarthritis, specifically its metabolism, mechanism of action, efficacy, and safety. A literature search was carried out, based on articles published in the last ten years, in &#8220;Pubmed&#8221; and &#8220;Sciencedirect&#8221; databases, using the descriptors &#8220;glucosamine&#8221; in association with &#8220;osteoarthritis&#8221; and &#8220;pharmacokinetics&#8221;. Official recommendations from health organizations were also considered. Orally administered glucosamine is absorbed in the duodenum and transported by GLUT-2 into cells. This compound participates in the hexosamine pathway, contributing to the biosynthesis of proteoglycans and glycoproteins, which are significant components of the extracellular matrix of the cartilage. In osteoarthritis, glucosamine has an anti-inflammatory and protective effect against cartilage degradation. According to the literature, the therapeutic dose of glucosamine capable of decreasing joint pain and improving function is 1500 mg/ day. The brand and formulation are essential factors for its effectiveness. This substance was considered safe, and no serious adverse effects or cases of overdose were observed. Glucosamine may have a positive effect on alleviating the symptoms of osteoarthritis. However, there is still no consensus on its efficacy, nutrient-drug interactions and impacts on glucose metabolism. Therefore, further studies are needed.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Dor articular]]></kwd>
<kwd lng="pt"><![CDATA[Glucosamina]]></kwd>
<kwd lng="pt"><![CDATA[Medicamento de ação lenta]]></kwd>
<kwd lng="pt"><![CDATA[Osteoartrite]]></kwd>
<kwd lng="pt"><![CDATA[Suplemento alimentar]]></kwd>
<kwd lng="en"><![CDATA[Joint pain]]></kwd>
<kwd lng="en"><![CDATA[Glucosamine]]></kwd>
<kwd lng="en"><![CDATA[Slow-acting drug]]></kwd>
<kwd lng="en"><![CDATA[Osteoarthritis]]></kwd>
<kwd lng="en"><![CDATA[Food supplement]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Salazar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bello]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucosamine for Osteoarthritis: Biological Effects, Clinical Efficacy, and Safety on Glucose Metabolism]]></article-title>
<source><![CDATA[Arthritis]]></source>
<year>2014</year>
<page-range>1-13</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinusas]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoarthritis: diagnosis and treatment]]></article-title>
<source><![CDATA[Am Fam Physician]]></source>
<year>2012</year>
<volume>85</volume>
<page-range>49-56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Honvo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Reginster]]></surname>
<given-names><![CDATA[J-Y]]></given-names>
</name>
<name>
<surname><![CDATA[Rabenda]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis]]></article-title>
<source><![CDATA[Drugs Aging]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bordalo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade de Carvalho]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
<name>
<surname><![CDATA[Oliveira]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Saúde dos Portugueses.]]></article-title>
<source><![CDATA[Perspetiva]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Lisboa ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beaudart]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lengelé]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Leclercq]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Symptomatic Efficacy of Pharmacological Treatments for Knee Osteoarthritis: A Systematic Review and a Network Meta-Analysis with a 6-Month Time Horizon]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2020</year>
<volume>80</volume>
<page-range>1947-59</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saengnipanthkul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Waikakul]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rojanasthien]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment]]></article-title>
<source><![CDATA[Int J Rheum Dis]]></source>
<year>2019</year>
<volume>22</volume>
<page-range>376-85</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gregori]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Giacovelli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Minto]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2018</year>
<volume>320</volume>
<page-range>2564</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henrotin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chondroitin and Glucosamine in the Management of Osteoarthritis: An Update]]></article-title>
<source><![CDATA[Curr Rheumatol Rep]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>361</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rovati]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Girolami]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Amato]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of glucosamine sulfate on the use of rescue non-steroidal anti-inflammatory drugs in knee osteoarthritis: Results from the Pharmaco- Epidemiology of GonArthroSis (PEGASus) study.]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2016</year>
<volume>45</volume>
<page-range>34-41</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dalirfardouei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Karimi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Jamialahmadi]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular mechanisms and biomedical applications of glucosamine as a potential multifunctional therapeutic agent]]></article-title>
<source><![CDATA[Life Sci]]></source>
<year>2016</year>
<volume>152</volume>
<page-range>21-9</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nakamura]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Application of glucosamine on human disease - Osteoarthritis]]></article-title>
<source><![CDATA[Carbohydr Polym]]></source>
<year>2011</year>
<volume>84</volume>
<page-range>835-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Du Souich]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absorption, distribution and mechanism of action of SYSADOAS]]></article-title>
<source><![CDATA[Pharmacol Ther]]></source>
<year>2014</year>
<volume>142</volume>
<page-range>362-374.</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henrotin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Mobasheri]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Marty]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2012</year>
<volume>14</volume>
<page-range>1-10</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bruyère]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Altman]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Reginster]]></surname>
<given-names><![CDATA[JY.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of glucosamine sulfate in the management of osteoarthritis: Evidence from real-life setting trials and surveys]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ali]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Badgley]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Oral glucosamine increases expression of transforming growth factor &#946;1 (TGF&#946;1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: Implications for human efficacy and toxicity.]]></article-title>
<source><![CDATA[Arch Biochem Biophys]]></source>
<year>2011</year>
<volume>510</volume>
<page-range>11-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kucharz]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kovalenko]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Szántó]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review of glucosamine for knee osteoarthritis: Why patented crystalline glucosamine sulfate should be differentiated from other glucosamines to maximize clinical outcomes]]></article-title>
<source><![CDATA[Current Medical Research and Opinion]]></source>
<year>2016</year>
<volume>32</volume>
<page-range>997-1004</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Reginster]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Neuprez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lecart]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of glucosamine in the treatment for osteoarthritis.]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2012</year>
<volume>32</volume>
<page-range>2959-67</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Sang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: A meta-analysis of randomized controlled trials.]]></article-title>
<source><![CDATA[J Orthop Surg Res]]></source>
<year>2018</year>
<volume>13</volume>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[GC]]></given-names>
</name>
<name>
<surname><![CDATA[Eyles]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dietary supplements for treating osteoarthritis: A systematic review and meta-Analysis]]></article-title>
<source><![CDATA[Br J Sports Med]]></source>
<year>2018</year>
<volume>52</volume>
<page-range>167-75</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<collab>European Medicines Authority</collab>
<source><![CDATA[Committee for medicinal products for human use (chmp) Opinion following an article 29(4)1 referral for glucomed and associated names International non-proprietary name (inn): glucosamine hydrochloride]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Qinna]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Shubbar]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Matalka]]></surname>
<given-names><![CDATA[KZ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucosamine enhances paracetamol bioavailability by reducing its metabolism]]></article-title>
<source><![CDATA[J Pharm Sci]]></source>
<year>2015</year>
<volume>104</volume>
<page-range>257-265.</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doshi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ostrovsky]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Glucosamine may be Effective in Treating Pain due to Knee Osteoarthritis.]]></article-title>
<source><![CDATA[EXPLORE]]></source>
<year>2019</year>
<volume>15</volume>
<page-range>317-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ogata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ideno]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Akai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis.]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2018</year>
<volume>37</volume>
<page-range>2479-87</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Henrotin]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Marty]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mobasheri]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[What is the current status of chondroitin sulfate and glucosamine for the treatment of knee osteoarthritis?]]></article-title>
<source><![CDATA[Maturitas]]></source>
<year>2014</year>
<volume>78</volume>
<page-range>184-7</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolasinski]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Neogi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 American College of Rheumatology/ Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2020</year>
<volume>72</volume>
<page-range>149-62</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bannuru]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Osani]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Vaysbrot]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.]]></article-title>
<source><![CDATA[Osteoarthr Cartil]]></source>
<year>2019</year>
<volume>27</volume>
<page-range>1578-89</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<collab>National Institute for Care and Health Excellence</collab>
<article-title xml:lang=""><![CDATA[Osteoarthritis : care and management]]></article-title>
<source><![CDATA[NICE Guidel.]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martins]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Ponte]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Mousinho]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Suplementos alimentares: o que são e como notificar reações adversas]]></article-title>
<source><![CDATA[Bol Farm - INFARMED]]></source>
<year>2017</year>
<volume>21</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="">
<collab>Infomed</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dixon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Marcel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Osteoarthritis : Nutritional Factors]]></article-title>
<source><![CDATA[Glendale: Cinahl Information Systems]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Browne]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rayman]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Food Fact Sheet Diet and osteoarthritis]]></article-title>
<source><![CDATA[Br Diet Assoc,]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
